Translating Mitochondrial Science into Medicine

ICM Therapeutics is developing therapies for infectious cardiomyopathy, polycystic kidney and liver disease (PKD/PLD), and oncology.

Under chronic stress, mitochondrial populations can shift toward stress-associated subpopulations associated with replicative stress, oxidative stress, altered metabolism, and cellular survival responses linked to disease progression. These adaptive responses are increasingly recognized as important drivers of chronic disease progression.

ICM Therapeutics is developing therapeutic approaches designed to target mitochondrial stress responses and cellular health. Our technology may provide new opportunities to intervene in cancer, heart failure, infectious disease, and serious genetic diseases.